All In Biotech

Free tool

FAERS Monitor: Relistor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208271 or its brand name (Relistor, Methylnaltrexone Bromide). Reports on generic versions are filed under their own applications.

Reports

1,520

Serious

905

60% of reports

Hospitalization

347

Death reported

335

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death246
  • drug ineffective208
  • nausea118
  • constipation113
  • abdominal pain106
  • pain84
  • diarrhoea81
  • vomiting77
  • fatigue67
  • headache58
  • abdominal pain upper57
  • off label use51
  • dyspnoea44
  • weight decreased44
  • malaise43

Reports by year received

View as table
YearReports
20041
200810
200938
201044
201161
201225
201325
201440
201549
2016144
2017166
2018137
2019217
2020148
2021109
202271
202362
202459
202561
202653

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
constipationSignal1137.26.0600
abdominal painSignal1066.35.2473
deathSignal2464.03.5562
abdominal pain upperSignal573.83.0118
vomitingSignal772.31.854
drug ineffectiveSignal2082.21.9141
weight decreasedSignal442.21.627
nauseaSignal1182.11.766
pain841.91.535
diarrhoea811.71.425
malaise431.41.04
headache581.31.03
fatigue671.20.92
dyspnoea441.10.80
off label use510.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.